Abstract | BACKGROUND: METHODS: We conducted a survey of state and city tuberculosis programs and other health care settings in the United States where rifampin- pyrazinamide was prescribed. The number of rifampin- pyrazinamide therapy initiations was collected, as well as the number of occurrences of (1) asymptomatic aspartate aminotransferase serum concentration >5 times the upper limit of normal, (2) symptomatic hepatitis (in which the patient was not hospitalized), (3) hospitalization for liver injury, (4) death with liver injury, and (5) treatment completion. We also searched a national pharmacy claims database (Verispan). Rates of these events were calculated. RESULTS: CONCLUSIONS:
|
Authors | Peter D McElroy, Kashef Ijaz, Lauren A Lambert, John A Jereb, Michael F Iademarco, Kenneth G Castro, Thomas R Navin |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 41
Issue 8
Pg. 1125-33
(Oct 15 2005)
ISSN: 1537-6591 [Electronic] United States |
PMID | 16163632
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antitubercular Agents
- Pyrazinamide
- Rifampin
|
Topics |
- Antitubercular Agents
(adverse effects, therapeutic use)
- Chemical and Drug Induced Liver Injury
- Health Surveys
- Hospitalization
(statistics & numerical data)
- Humans
- Liver Diseases
(epidemiology)
- Pyrazinamide
(adverse effects, therapeutic use)
- Rifampin
(adverse effects, therapeutic use)
- Tuberculosis
(drug therapy)
- United States
(epidemiology)
|